GE HealthCare, BAMF Health collaborate for Theranostics solutions

As demand for Theranostic care increases, GE HealthCare and BAMF Health announced a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services. The goal of the collaboration is to ensure an agile go-to-market approach to enhance the adoption of Theranostics solutions in the U.S. The arrangement supports a shared interest in better patient outcomes made possible through advanced diagnostics and radiotherapeutics. Theranostics in molecular imaging uses both imaging technology and targeted therapies to identify and treat diseases such as cancer as well monitor response to treatment; the term originates from the way this form of personalized medicine is practiced – the combination of therapy and diagnostics. Connecting all phases of the Theranostics care pathway, from drug development through disease diagnosis and treatment monitoring, with scalable solutions, connectivity, and advanced imaging technologies, is critical to helping clinicians and health systems bring Theranostics treatments to more patients. The collaboration between GE HealthCare and BAMF Health will leverage both partners’ deep understanding of the complexities of delivering Theranostic care to establish a framework to support the scalable infrastructure and clinical solutions for expanded adoption of precision care.